

The advanced dose.
Anti-aging 55+ is a 120-minute intravenous infusion of 500 mg NAD⁺ — twice the Anti-aging 35+ dose, delivered slowly enough to avoid the flushing response that fast infusion produces. For clients already on an established Anti-aging 35+ cadence with documented tolerance and reviewed bloodwork.
The advanced dose. NAD⁺ at 500 mg, infused over two hours.
- Twice the Anti-aging 35+ dose, infused slowly over two hours
- Stronger metabolic lift, lasting up to two weeks
- Recovery after illness or extended physical stress
- Quarterly — only after a documented Anti-aging 35+ baseline
Composition
Mixed in our laboratory immediately before the session. Weighed, recorded, and signed off against your individual case.
The science.
Anti-aging 55+ doubles the Anti-aging 35+ dose to 500 mg of NAD⁺ in a single intravenous session. The 120-minute infusion is medically necessary — at this dose, faster delivery causes facial flushing, chest tightness, and occasionally elevated blood pressure.
Doubling the dose increases cellular uptake at saturation but also requires baseline tolerance and case review. We do not run Anti-aging 55+ as a first NAD⁺ session; clients begin at Anti-aging 35+, document tolerance and effect, and progress to Anti-aging 55+ once markers are reviewed.
500 mg is the ceiling dose offered at INFUZE. Above this — at 750 or 1000 mg per session as used in some clinics — the marginal cellular uptake of NAD⁺ in healthy adults is poorly characterised in the literature, while the rate of vagal and cardiovascular side effects rises sharply. We chose to stop at the dose with a documented safety and tolerability margin rather than chase a number.
The protocol pairs cleanly with quarterly Detox sessions for clients running ongoing longevity protocols. Each Anti-aging 55+ session is mixed in our laboratory and the full dose recorded against your case file.
Two layers, one session.
Every Anti-aging 55+ session pairs the infusion with targeted electrical stimulation. The chemistry restores; the stim addresses what the infusion can’t reach by molecules alone.
Anti-aging 55+ runs 500 mg NAD⁺ slow-infused over two hours under full clinical attention. The neurotherapy layer is intentionally minimal — gentle support only — so the monitoring channels stay clean. Premium care here means doing less, not more.

What the session is like.
Two hours is intentional — slow infusion, slow uptake, no flushing or chest pressure. Most clients bring a book or sleep through the second half. The room is quiet.
Mental clarity is the typical post-session report; the metabolic effect lasts up to two weeks. Clients on Anti-aging 55+ quarterly protocols often describe a sustained baseline lift after the third session.
Protocol cadence.
Anti-aging 55+ requires a baseline session at the Anti-aging 35+ dose first, plus a documented intake review of current markers. Quarterly cadence is the standard once you're on Anti-aging 55+ — single doses are not the right framing.

Who it’s for.
Three contexts where Anti-aging 55+ delivers the most measurable change.
- 01 · Indication
Established Anti-aging 35+ clients with documented baseline
- 02 · Indication
Post-illness cellular recovery, under case review
- 03 · Indication
Quarterly maintenance once tolerance is confirmed
Before you book.
Why does the session take 2 hours?
Slow infusion is the safety margin. NAD⁺ at 500 mg infused under 90 minutes consistently produces facial flushing, chest pressure, and occasionally a vagal response. 120 minutes is the documented safe range.
Do I need a consultation first?
Yes. Anti-aging 55+ requires a baseline Anti-aging 35+ session and an intake review of your current markers and medications before we'll proceed at the higher dose.
Can I sleep through it?
Most clients do. Bring a book, headphones, or a podcast — the room is quiet and the line is comfortable for the duration.
How often should I do Anti-aging 55+?
Quarterly is the standard cadence after baseline tolerance is established. Some clients run it more frequently during post-illness recovery, with case review every 12 weeks.
